Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12211MR)

This product GTTS-WQ12211MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12211MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10404MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ15292MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ845MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ13302MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ5441MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ4369MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ12240MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ12174MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW